Our life goal is to make yours better.
CVRx® is a privately held company founded in 2001 and headquartered in Minneapolis, U.S.A. Our vision is to advance health for people everywhere, giving each patient a fuller life. CVRx® pioneers unique therapies that harness and harmonize the body's natural systems, benefiting society and making CVRx® a universal role model in healthcare.

Pioneering a Unique Therapy
BAROSTIM NEO™ is the only device CE Marked for the separate indications of heart failure and resistant hypertension. Currently, BAROSTIM NEO™ is commercially available in over 20 countries and under clinical evaluation for the treatment of heart failure and hypertension in the United States.
Learn More About Barostim Neo™

Our History
-
2001
CVRx® established in Minneapolis, Minnesota, USA
-
2004
First patient treated with the first-generation BAROSTIM THERAPY™ device in Bern University Hospital (Switzerland)
-
2005
First patient treated in the US
-
2006
Early findings from DEBuT-HT Hypertension trial, showing significant reductions in blood pressure, are presented at the American Heart Association congress
-
2007
First-generation BAROSTIM THERAPY™ device receives CE-mark approval for resistant hypertension
-
2008
Two-year results of DEBuT-HT Hypertension trial confirm first-generation BAROSTIM THERAPY™ device’s significant blood pressure reduction
-
2011
Introduction of the BAROSTIM NEO™ device, which receives CE-mark approval for resistant hypertension
-
Jun 2014
Publication of a "Proof-of-concept" study in Heart Failure concluding that BAROSTIM NEO™ is safe and provides chronic improvement to patients
-
Sep 2014
BAROSTIM NEO™ receives CE-mark approval for the treatment of heart failure
-
Dec 2014
BAROSTIM NEO™ LEGACY granted Humanitarian Device Exemption by FDA for Hypertensive patients who were defined as responders to the Rheos Carotid Sinus Lead System
-
May 2015
1000 patients treated with BAROSTIM THERAPY™
-
Jun 2015
Results of BAROSTIM THERAPY™ for Heart Failure randomized study presented at several international congresses
-
Nov 2015
Expedited Access Pathway designation granted by FDA for BAROSTIM THERAPY™ for the treatment of heart failure
-
Jun 2016
First patients treated in pivotal trial evaluating BAROSTIM THERAPY™ in heart failure (BeAT-HF)